🔴 NMRA is trading 5.5% down today as shares drift lower following failed Phase 3 trials

NMRA is trading at $1.64 (5.5% down) as shares continue to drift lower following June’s sharp selloff tied to failed Phase 3 KOASTAL trials and the discontinuation of navacaprant.

• The stock remains under pressure with no fresh company-specific news reported for July 8, 2026.
• The downward move aligns with broader volatility in the biotech sector and a general risk-off sentiment as major indices trade lower.